Company
Clearside Biomedical
IP holding company commercializing SCS ocular drug-delivery platform and microinjector technology.
Also known as Clearside Bio, Clearside Biomedical, Inc.
- Status
- IPOas of 2026-09-23Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- New York, NY, United States
- Legal name
- Clearside Biomedical, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases. IPO in June, 2016 (NASDAQ:CLSD).
Funding snapshot
- Total raised
- $48.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $3.3M2019-11-26
Funding rounds
- Round, 2019
- $3.3M2019-11-26, SEC form D sold, 3 investors
- Round, 2016
- $320K2016-09-28, SEC form D sold, 2 investors
- Round, 2015
- $14.4M2015-11-23, SEC form D sold, 9 investors
- Round, 2014
- $16.2M2014-08-29, SEC form D sold, 31 investors
- Round, 2014
- $3M2014-04-28, SEC form D sold, 13 investors
- Round, 2013
- $7.9M2013-01-31, SEC form D sold, 13 investors
- Round, 2012
- $3.2M2012-01-03, SEC form D sold, 7 investors
About the company
- Status notes
- IPO in June, 2016 (NASDAQ:CLSD)
Products
- Web
- microinjector technology
- Web
- suprachoroidal space (SCS) ocular drug-delivery platform
Loading relationship preview